Skip to Main content Skip to Navigation
New interface
Journal articles

Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy

Abstract : Rabies is a severe viral infection that causes an acute encephalomyelitis, which presents a case fatality of nearly 100% after the manifestation of neurological clinical signs. Rabies can be efficiently prevented with post-exposure prophylaxis (PEP), composed of vaccines and anti-rabies immunoglobulins (RIGs); however, no treatment exists for symptomatic rabies. The PEP protocol faces access and implementation obstacles in resource-limited settings, which could be partially overcome by substituting RIGs for monoclonal antibodies (mAbs). mAbs offer lower production costs, consistent supply availability, long-term storage/stability, and an improved safety profile. Here we summarize the key features of the different available mAbs against rabies, focusing on their application in PEP and highlighting their potential in a novel therapeutic approach.
Document type :
Journal articles
Complete list of metadata
Contributor : Guilherme Dias de Melo Connect in order to contact the contributor
Submitted on : Monday, October 24, 2022 - 6:30:57 PM
Last modification on : Thursday, November 3, 2022 - 3:52:07 AM


Publication funded by an institution


Distributed under a Creative Commons Attribution - NonCommercial - NoDerivatives 4.0 International License




Guilherme Dias de Melo, Jan Hellert, Rajesh Gupta, Davide Corti, Hervé Bourhy. Monoclonal antibodies against rabies: current uses in prophylaxis and in therapy. Current Opinion in Virology, 2022, 53, pp.101204. ⟨10.1016/j.coviro.2022.101204⟩. ⟨pasteur-03827722⟩



Record views


Files downloads